What development phase is OXAPROZIN POTASSIUM in?

OXAPROZIN POTASSIUM is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

OXAPROZIN POTASSIUM

FDA-approved approved Small molecule Quality 0/100

OXAPROZIN POTASSIUM is a marketed drug with a key composition patent expiring in 2028. The drug's primary indication and mechanism are not specified, but its market position is bolstered by its current availability and patent protection. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	OXAPROZIN POTASSIUM
Modality	Small molecule
Phase	FDA-approved
First approval	2002

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Drug-drug Interaction Study of FYU-981 and Oxaprozin (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

OXAPROZIN POTASSIUM CI brief — competitive landscape report
OXAPROZIN POTASSIUM updates RSS · CI watch RSS